Flecainide

Introduction Overview

Generic Name

flecainide

Brand Name

Tambocor

Dosage Form

oral tablet (50 mg; 100 mg; 150 mg)

Drug Class

Group I antiarrhythmics, Class IC anti-arrhythmic

Pharmacokinetics

Absorption:
Flecainide is well absorbed orally, with nearly complete bioavailability following oral administration. Peak plasma concentrations are generally achieved within 1 to 3 hours after dosing. The rate and extent of absorption are not significantly affected by food, allowing flexible dosing with or without meals. Monitoring plasma levels may be needed in special populations to avoid toxicity.

Distribution:
The volume of distribution of flecainide is moderate, generally approximating total body water, indicating extensive tissue penetration including cardiac muscle. Flecainide is approximately 40% plasma protein bound, primarily to albumin. It readily crosses cellular membranes and concentrates within myocardial tissue, which is its site of action. Flecainide has also been reported to cross the placenta, and limited data exist on its distribution into breast milk.

Metabolism:
Flecainide undergoes hepatic metabolism primarily via the cytochrome P450 system, specifically CYP2D6 isoenzyme. The metabolic pathways generate inactive metabolites, but genetic polymorphisms in CYP2D6 activity can significantly influence flecainide plasma concentrations and clinical response, necessitating careful dosing adjustments in poor metabolizers. Approximately 30% of the dose is metabolized hepatically.

Elimination:
Elimination of flecainide occurs via both renal excretion and hepatic metabolism. Approximately 30-50% of the administered dose is excreted unchanged in the urine. The elimination half-life ranges between 12 to 27 hours in healthy individuals but may be prolonged in patients with renal impairment or congestive heart failure, necessitating dose adjustment and careful monitoring. Steady-state concentrations are typically achieved within 3 to 5 days of dosing.

Dosage Forms

Available Dosage Forms:
Flecainide is commercially available as oral tablets in strengths of 50 mg, 100 mg, and 150 mg.

Dosages for Adults and Adolescents:
- For ventricular tachycardia: Initial dose usually 100 mg orally every 12 hours, with increments of 50 mg every 12 hours every 4 days until efficacy is achieved. Maximum dose is 400 mg/day.
- For atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, and paroxysmal supraventricular tachycardia: Initial dose commonly 50 mg orally every 12 hours; maintenance dosing titrated in increments of 50 mg every 12 hours every 4 days based on clinical response.

Specific Patient Populations:
- Pediatric patients: Dosing varies with age and weight. Neonates (<1 month) may start at 2 mg/kg/day orally divided every 12 hours; older children (≥1 month) typically start at 1 to 3 mg/kg/day orally in three divided doses, titrated to effect.
- Patients with renal or hepatic impairment require careful dose adjustment and therapeutic drug monitoring due to altered pharmacokinetics.
- Elderly patients may require dose modification due to reduced clearance.

Clinical guidelines emphasize individualized dosing and close ECG monitoring during dose titration, especially during initiation in a hospital or clinic setting to manage potential proarrhythmic effects.

Mechanism Of Action

Flecainide is a potent Class IC antiarrhythmic agent that acts primarily by blocking the fast inward sodium channels (Na+ channels) in cardiac myocytes. This blockade leads to a marked reduction in the rate of depolarization (phase 0 of the cardiac action potential), effectively slowing conduction velocity throughout all cardiac tissue, including the atria, ventricles, and His-Purkinje system.

At the cellular level, the sodium channel inhibition stabilizes the cardiac membrane by decreasing excitability and preventing the propagation of aberrant electrical impulses that underlie arrhythmias. Unlike other antiarrhythmics, flecainide causes minimal changes to the duration of the action potential and refractoriness, making it unique in its ability to suppress arrhythmias without significantly prolonging repolarization.

Additionally, flecainide has some inhibitory effects on potassium channels and weak calcium channel blocking activity, which may further contribute to its antiarrhythmic effects. Its noncompetitive blockade and slow unbinding kinetics account for the marked use-dependence, preferentially targeting rapidly firing or ectopic cardiac tissues, which is valuable in managing tachyarrhythmias.

Clinical implications include its efficacy in suppressing ventricular tachycardia and controlling paroxysmal atrial arrhythmias; however, due to proarrhythmic risk especially in structural heart disease, flecainide is generally reserved for patients without significant left ventricular dysfunction. Comparative studies indicate that although other sodium channel blockers like propafenone share similar actions, flecainide is often favored for its potency and predictable pharmacokinetics. Extensive clinical trials have established flecainide's role in rhythm control strategies for supraventricular and ventricular arrhythmias.

Pharmacological Actions

Class IC antiarrhythmic agent with potent sodium channel blockade.
Slows cardiac impulse conduction by inhibiting phase 0 depolarization of the action potential.
Reduces excitability and stabilizes myocardial membranes.
Exhibits use-dependent blockade, targeting rapidly firing cardiac tissues.
Suppresses ectopic pacemakers and abnormal automaticity in atrial and ventricular myocardium.
Mild inhibitory effects on potassium and calcium channels, aiding antiarrhythmic efficacy.
Decreases propagation of abnormal electrical impulses responsible for arrhythmias.
Does not significantly prolong repolarization or refractory periods.
Effectively used for rhythm control in supraventricular tachyarrhythmias and ventricular tachycardia.
Crosses the placenta and is excreted in breast milk.
Metabolized primarily by hepatic CYP2D6 system with variable metabolism based on genetic polymorphisms.

Therapeutic Or Clinical Uses

Treatment and prevention of ventricular tachycardia (VT).
Management of paroxysmal supraventricular tachycardia (PSVT).
Rhythm control in atrial fibrillation (AFib), including chronic AF.
Management of atrial flutter.
Treatment of arrhythmias associated with Wolff-Parkinson-White syndrome.
Off-label use for other complex atrial or ventricular arrhythmias as determined by cardiologist.
Used in patients without significant structural heart disease or left ventricular dysfunction.
Adjunct therapy in patients with implantable cardioverter-defibrillators to reduce shock frequency.
Empirical treatment for life-threatening ventricular arrhythmias when other antiarrhythmics are ineffective.
Therapeutic option for patients intolerant or refractory to beta-blockers and other antiarrhythmic drugs.

Side Or Adverse Effects

Cardiac arrhythmias including new or worsened ventricular arrhythmias (proarrhythmia).
Dizziness and visual disturbances such as blurred vision or scotomata.
Headache.
Nausea and gastrointestinal discomfort.
Fatigue and generalized weakness.
Dyspnea and shortness of breath.
Bradycardia, slow heart rate, or conduction block leading to pacemaker requirement.
Palpitations and chest fluttering sensations.
Allergic reactions including rash and, rarely, angioedema.
Edema, swelling, and rapid weight gain due to fluid retention.
Rare cases of hepatic dysfunction and jaundice.
Neurologic symptoms including tremor and seizures in overdose.
Electrolyte imbalances may exacerbate adverse effects.

Precautions

Use with caution in patients with structural heart disease or prior myocardial infarction due to increased risk of proarrhythmia.
Monitor ECG and cardiac function closely, especially during initiation and dose adjustments.
Regularly assess liver and renal function to guide dosing and prevent toxicity.
Avoid use in patients with bundle branch block or AV block unless a pacemaker is implanted.
Maintain normal serum potassium and magnesium levels to reduce arrhythmia risk.
Avoid abrupt discontinuation to prevent rebound arrhythmias.
Initiate therapy in a hospital setting where ECG monitoring and resuscitation facilities are available.
Caution in elderly due to altered metabolism and clearance.
Use cautiously in patients with sick sinus syndrome or other conduction abnormalities.
Screen for drug interactions, especially with other antiarrhythmics, beta-blockers, and CYP2D6 inhibitors.
Evaluate pregnancy status as fetal safety data is limited.
Cautious use during breastfeeding; assess risk versus benefit.
Adjust doses in renal or hepatic impairment.
Advise patients to report symptoms of heart failure or arrhythmia worsening promptly.

Warnings

Contraindicated in patients with preexisting bundle branch block or AV block unless they have a functioning pacemaker.
Avoid use in patients with severe left ventricular dysfunction or congestive heart failure due to proarrhythmic risk.
First dose should be administered under medical supervision with ECG monitoring due to potential for serious arrhythmias.
Risk of life-threatening ventricular arrhythmias including polymorphic ventricular tachycardia and fibrillation.
May exacerbate heart failure symptoms; monitor for fluid retention and worsening cardiac function.
Potential for fatal arrhythmias in overdose; prompt medical attention required.
Use with caution in patients with electrolyte disturbances, particularly hypokalemia or hypomagnesemia.
Flecainide may cause dizziness and visual disturbances, increasing risk of falls.
Avoid in patients with known hypersensitivity to flecainide or any formulation components.
Pregnancy safety is not established; use only if clearly needed.
Monitor for signs of allergic reactions including angioedema and anaphylaxis.
Concomitant use with other arrhythmogenic drugs requires careful ECG and clinical monitoring.
Baseline and periodic ECG and cardiac monitoring are essential during therapy.

Contraindication

Known hypersensitivity or allergy to flecainide.
Presence of bundle branch block or AV block without a pacemaker.
Severe left ventricular dysfunction or congestive heart failure.
History of cardiogenic shock or unstable hemodynamics.
Past history of significant ventricular arrhythmias exacerbated by sodium channel blockers.
Concomitant use with drugs contraindicated due to severe interactions.
Patients with sick sinus syndrome or other significant conduction system disease without a pacemaker.
Severe electrolyte imbalances not corrected prior to initiation.
Pregnancy and lactation when benefits do not justify risks (caution advised).

Drug Interactions

Increased risk of arrhythmias when combined with other antiarrhythmics such as amiodarone, quinidine, disopyramide, or propafenone.
Beta-blockers (atenolol, metoprolol, propranolol, sotalol) may have additive effects on cardiac conduction and contractility.
Concomitant digoxin use may increase digoxin plasma concentrations or effects.
Calcium channel blockers like diltiazem and verapamil enhance cardiac conduction slowing leading to bradycardia or heart block.
Diuretics causing electrolyte disturbances (e.g., hypokalemia) may potentiate flecainide-related arrhythmias.
CYP2D6 inhibitors may elevate flecainide plasma levels, increasing toxicity risk.
Seizure medications may interact altering flecainide metabolism.
Other drugs prolonging QRS or QT interval can potentiate proarrhythmic effects.
Herbal supplements with cardiac effects or cytochrome P450 interactions may alter flecainide pharmacodynamics.
Caution with anticoagulants due to overlapping cardiac risks but no direct pharmacokinetic interactions.
NSAIDs without significant documented interactions but monitor for fluid retention.

Preparations Of The Drug

Oral tablets: 50 mg strength for initiation and titration.
Oral tablets: 100 mg strength commonly used for maintenance therapy.
Oral tablets: 150 mg strength for dose escalation in refractory cases.
Packaging typically in blister packs or bottles for oral administration.
Stored at room temperature away from excessive moisture, heat, and light.
No intravenous or parenteral formulations are widely available.
Manufactured under strict quality control to ensure dosage accuracy.
Available under brand name Tambocor and generic formulations.
Patient information leaflets included with each preparation emphasizing dosing and safety.
Clinical supplies intended for use under medical supervision due to potential risks.